Laleh Sharifi1, Zahra Pourpak1, Mohammad Reza Fazlollahi1, Saied Bokaie2, Hamid Reza Moezzi3, Anoushirvan Kazemnejad4, Mostafa Moin1. 1. Immunology, Asthma and Allergy Research Institute, Tehran University of Medical Sciences, Tehran, Iran. 2. Dept. of Epidemiology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran. 3. Department of Lung Diseases, Milad Hospital, Tehran, Iran. 4. Dept. of Biostatistics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Abstract
BACKGROUND: High prevalence and increasing rate of asthmatic patients around the word witnesses the high burden of asthma. We have limited data on asthma burden and economic costs in Iran. This study aimed to find direct and indirect economic costs of asthma and their association with some background factors in one of the referral tertiary centers for adult patients with asthma. METHODS: We surveyed asthma related economic costs of 197 adult patients who referred to Milad Hospital, Tehran, Iran from Jun 2007 to January 2010. The patients were followed up for a period of one-year ±1 month and asthma related costs and its control status were registered. RESULTS: Patients were consisted of 125 (64.1%) females and 70 (35.9%) males. Total cost of asthma was 590.22 ±32.18 USD for one patient per one year, the cost of drug, paraclinic, doctor visit, hospitalization, emergency, transportation, and absent days were 327.02, 4.76, 35.44, 3.82, 0.26, 113.03, 105.89 USD respectively. Men showed a significant elevation in their total (P=0.009) and drug costs (P=0.028). In addition, we found significant differences between total asthma costs and asthma control status (P=0.002). CONCLUSIONS: According to the high proportion of asthma, related cost compare to Total Income of an Iranian family, the necessity of public coverage of health assurance is quite clear. We suggest that improving asthma management and accessibility to specialized treatment centers can result in decreasing asthma medication and transportation costs as major direct and indirect asthma related costs.
BACKGROUND: High prevalence and increasing rate of asthmatic patients around the word witnesses the high burden of asthma. We have limited data on asthma burden and economic costs in Iran. This study aimed to find direct and indirect economic costs of asthma and their association with some background factors in one of the referral tertiary centers for adult patients with asthma. METHODS: We surveyed asthma related economic costs of 197 adult patients who referred to Milad Hospital, Tehran, Iran from Jun 2007 to January 2010. The patients were followed up for a period of one-year ±1 month and asthma related costs and its control status were registered. RESULTS:Patients were consisted of 125 (64.1%) females and 70 (35.9%) males. Total cost of asthma was 590.22 ±32.18 USD for one patient per one year, the cost of drug, paraclinic, doctor visit, hospitalization, emergency, transportation, and absent days were 327.02, 4.76, 35.44, 3.82, 0.26, 113.03, 105.89 USD respectively. Men showed a significant elevation in their total (P=0.009) and drug costs (P=0.028). In addition, we found significant differences between total asthma costs and asthma control status (P=0.002). CONCLUSIONS: According to the high proportion of asthma, related cost compare to Total Income of an Iranian family, the necessity of public coverage of health assurance is quite clear. We suggest that improving asthma management and accessibility to specialized treatment centers can result in decreasing asthma medication and transportation costs as major direct and indirect asthma related costs.
Entities:
Keywords:
Asthma; Direct cost; Indirect cost; Iran
Authors: K F Chung; P Godard; E Adelroth; J Ayres; N Barnes; P Barnes; E Bel; P Burney; P Chanez; G Connett; C Corrigan; J de Blic; L Fabbri; S T Holgate; P Ind; G Joos; H Kerstjens; P Leuenberger; C G Lofdahl; S McKenzie; H Magnussen; D Postma; M Saetta; S Salmeron; P Sterk Journal: Eur Respir J Date: 1999-05 Impact factor: 16.671
Authors: Tina V Hartert; Theodore Speroff; Alkis Togias; Edward F Mitchel; Mary S Snowden; Robert S Dittus; Marie R Griffin Journal: Ann Allergy Asthma Immunol Date: 2002-11 Impact factor: 6.347
Authors: L Antonicelli; C Bucca; M Neri; F De Benedetto; P Sabbatani; F Bonifazi; H G Eichler; Q Zhang; D D Yin Journal: Eur Respir J Date: 2004-05 Impact factor: 16.671